药物发现服务的全球市场：市场规模和份额分析（按工艺、类型、药物类型、治疗领域和最终用户）、行业需求预测（截至 2030 年）

市场概况

2023年全球药物发现服务市场规模预估为210亿美元，预计2030年将达542亿美元。 2024 年至 2030 年复合年增长率为 14.7%。

生物製药和製药行业不断增加的研发投入、对分析测试设施外包的需求不断增长、研究罕见药物和罕见疾病的步伐以及内部药物开发的高成本正在为世界范围内的问题打开大门为行业带来新的收入。

关键见解

2023年，在药物发现服务业中，Hit-to-Lead识别类别占最大份额，达到35%。

到2023年，化学品类别将以60%的市占率占据首位。

小分子药物类别在业界占有很大份额，对于全球新疗法的出现至关重要。 2020年，小分子药物占特种药物销售额的50%，占FDA核准量的75%以上。

近年来，北美地区在药物开发服务方面占据了最大的行业份额，达到55%。

本报告分析了全球药物发现服务市场，包括市场的基本结构、最新情况、主要促进和抑制因素以及全球、按地区和主要国家的市场规模前景（关于以货币为基础，2017-2030 ），按工艺、类型、药物类型、治疗领域和最终用户划分的详细趋势、市场竞争的现状以及主要公司的概况。

目录

第1章研究范围

第2章研究方法

第 3 章执行摘要

第 4 章市场指标

第5章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/挑战
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第6章世界市场

• 摘要
• 市场收入：依流程分类（2017-2030 年）
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依药物类型划分（2017-2030 年）
• 市场收入：依治疗领域划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：按地区划分（2017-2030 年）

第7章北美市场

• 摘要
• 市场收入：依流程分类（2017-2030 年）
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依药物类型划分（2017-2030 年）
• 市场收入：依治疗领域划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第11章中东及非洲市场

第12章美国市场

• 摘要
• 市场收入：依流程分类（2017-2030 年）
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依药物类型划分（2017-2030 年）
• 市场收入：依治疗领域划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）

第13章加拿大市场

第14章德国市场

第15章法国市场

第16章英国市场

第17章义大利市场

第18章西班牙市场

第19章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其提供的产品/服务的列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Charles River Laboratories International Inc.
• Eurofins Scientific Limited
• Frontage Laboratories Inc.
• Galapagos NV
• General Electric
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Syngene International Limited
• WuXi AppTec

第31章 附录

Market Overview

In 2023, the estimated value of the global drug discovery services market is USD 21.0 billion, projected to reach USD 54.2 billion by 2030. This growth represents a Compound Annual Growth Rate of 14.7% during the period from 2024 to 2030.

The growing research and development investments of the biopharmaceutical and pharmaceutical industries, the increasing need for outsourcing analytical testing facilities, steps for orphan drug and rare illness research, and the costly nature of the in-house drug expansion procedure are all opening up new revenue gates in the worldwide industry.

One of the reasons for the escalating demand for outsourcing clinical testing and analytical research services for biopharmaceutical drugs is the rising expenditure of R&D activities that are majorly channelled toward orphan drugs that are meant to suppress rare conditions.

On the other hand, the biopharmaceutical industry has been growing exceptionally due to the ever-increasing demands for biologics and the invention of and manufacturing of several innovative and life-saving drugs. Moreover, the bioscience industry profits from the investment in research of the new covered drugs for common and rare diseases. The market of drug discovery is also solving the problem of patents' expiration as well as the growing need for biologics in emerging economies.

Key Insights

In 2023, the hit-to-lead identification category held the largest share of 35% in the drug discovery services industry.

This procedure is vital in initial drug research and includes outsourcing to attain economies of scale and effectiveness for medicinal businesses.

Pioneering in-silico methods such as computer-aided drug discovery and structure-based medication designs contribute to the development of this category.

High-throughput screening plays a major role in hit-to-lead identification, eased by improvements in robotics, liquid management, plate reader discovery, and computing power.

Because of the dedicated and expensive nature of HTS, several organizations, particularly those with limited backing, select to outsource such services to Contract Research Organizations for high-quality and lucrative solutions.

In 2023, the chemistry category grips a leading share of 60% in the market.

Besides drug discovery, medicinal chemistry provides action at every stage, starting from pre-clinical evaluation to the delivery of a drug candidate.

The medical chemistry market is growing as companies work to find new ways to outsource tasks such as R&D services.

Such growth is continuously fostered by an increase in the number of overhead costs incurred during the pharmaceutical discovery and development processes.

Small-molecule drugs category grips a substantial industry share and is vital in emerging novel treatments worldwide.

Small-molecule drugs account for 50% of specialty drug sales and comprised over 75% of all FDA approvals in 2020.

They play a critical role in treating cancer, autoimmune diseases, cardiovascular disorders, and respiratory conditions.

The North American region holds the largest industry share of 55% in the recent years in drug advancement services.

The region aids from several Contract Research Organizations and Contract Manufacturing Organizations backing key pharmaceutical and biopharmaceutical firms, contributing to industry growth.

Numerous newly developed drugs have their patents held in the U.S., additionally boosting the industry.

Reasons propelling industry development include an increasing elderly populace, growing occurrence of chronic illnesses, technical improvements in biotechnology and pharmaceutical industries, recognized reimbursement guidelines, advanced medicinal infrastructure, rising awareness of initial disease diagnosis, and the reequipment for better patient care.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by process
  • 1.4.2. Market size breakdown, by type
  • 1.4.3. Market size breakdown, by drug type
  • 1.4.4. Market size breakdown, by therapeutic area
  • 1.4.5. Market size breakdown, by end user
  • 1.4.6. Market size breakdown, by region
  • 1.4.7. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Process (2017-2030)
• 6.3. Market Revenue, by Type (2017-2030)
• 6.4. Market Revenue, by Drug Type (2017-2030)
• 6.5. Market Revenue, by Therapeutic Area (2017-2030)
• 6.6. Market Revenue, by End User (2017-2030)
• 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Process (2017-2030)
• 7.3. Market Revenue, by Type (2017-2030)
• 7.4. Market Revenue, by Drug Type (2017-2030)
• 7.5. Market Revenue, by Therapeutic Area (2017-2030)
• 7.6. Market Revenue, by End User (2017-2030)
• 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Process (2017-2030)
• 8.3. Market Revenue, by Type (2017-2030)
• 8.4. Market Revenue, by Drug Type (2017-2030)
• 8.5. Market Revenue, by Therapeutic Area (2017-2030)
• 8.6. Market Revenue, by End User (2017-2030)
• 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Process (2017-2030)
• 9.3. Market Revenue, by Type (2017-2030)
• 9.4. Market Revenue, by Drug Type (2017-2030)
• 9.5. Market Revenue, by Therapeutic Area (2017-2030)
• 9.6. Market Revenue, by End User (2017-2030)
• 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Process (2017-2030)
• 10.3. Market Revenue, by Type (2017-2030)
• 10.4. Market Revenue, by Drug Type (2017-2030)
• 10.5. Market Revenue, by Therapeutic Area (2017-2030)
• 10.6. Market Revenue, by End User (2017-2030)
• 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Process (2017-2030)
• 11.3. Market Revenue, by Type (2017-2030)
• 11.4. Market Revenue, by Drug Type (2017-2030)
• 11.5. Market Revenue, by Therapeutic Area (2017-2030)
• 11.6. Market Revenue, by End User (2017-2030)
• 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Process (2017-2030)
• 12.3. Market Revenue, by Type (2017-2030)
• 12.4. Market Revenue, by Drug Type (2017-2030)
• 12.5. Market Revenue, by Therapeutic Area (2017-2030)
• 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Process (2017-2030)
• 13.3. Market Revenue, by Type (2017-2030)
• 13.4. Market Revenue, by Drug Type (2017-2030)
• 13.5. Market Revenue, by Therapeutic Area (2017-2030)
• 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Process (2017-2030)
• 14.3. Market Revenue, by Type (2017-2030)
• 14.4. Market Revenue, by Drug Type (2017-2030)
• 14.5. Market Revenue, by Therapeutic Area (2017-2030)
• 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Process (2017-2030)
• 15.3. Market Revenue, by Type (2017-2030)
• 15.4. Market Revenue, by Drug Type (2017-2030)
• 15.5. Market Revenue, by Therapeutic Area (2017-2030)
• 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Process (2017-2030)
• 16.3. Market Revenue, by Type (2017-2030)
• 16.4. Market Revenue, by Drug Type (2017-2030)
• 16.5. Market Revenue, by Therapeutic Area (2017-2030)
• 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Process (2017-2030)
• 17.3. Market Revenue, by Type (2017-2030)
• 17.4. Market Revenue, by Drug Type (2017-2030)
• 17.5. Market Revenue, by Therapeutic Area (2017-2030)
• 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Process (2017-2030)
• 18.3. Market Revenue, by Type (2017-2030)
• 18.4. Market Revenue, by Drug Type (2017-2030)
• 18.5. Market Revenue, by Therapeutic Area (2017-2030)
• 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Process (2017-2030)
• 19.3. Market Revenue, by Type (2017-2030)
• 19.4. Market Revenue, by Drug Type (2017-2030)
• 19.5. Market Revenue, by Therapeutic Area (2017-2030)
• 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Process (2017-2030)
• 20.3. Market Revenue, by Type (2017-2030)
• 20.4. Market Revenue, by Drug Type (2017-2030)
• 20.5. Market Revenue, by Therapeutic Area (2017-2030)
• 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Process (2017-2030)
• 21.3. Market Revenue, by Type (2017-2030)
• 21.4. Market Revenue, by Drug Type (2017-2030)
• 21.5. Market Revenue, by Therapeutic Area (2017-2030)
• 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Process (2017-2030)
• 22.3. Market Revenue, by Type (2017-2030)
• 22.4. Market Revenue, by Drug Type (2017-2030)
• 22.5. Market Revenue, by Therapeutic Area (2017-2030)
• 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Process (2017-2030)
• 23.3. Market Revenue, by Type (2017-2030)
• 23.4. Market Revenue, by Drug Type (2017-2030)
• 23.5. Market Revenue, by Therapeutic Area (2017-2030)
• 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Process (2017-2030)
• 24.3. Market Revenue, by Type (2017-2030)
• 24.4. Market Revenue, by Drug Type (2017-2030)
• 24.5. Market Revenue, by Therapeutic Area (2017-2030)
• 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Process (2017-2030)
• 25.3. Market Revenue, by Type (2017-2030)
• 25.4. Market Revenue, by Drug Type (2017-2030)
• 25.5. Market Revenue, by Therapeutic Area (2017-2030)
• 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Process (2017-2030)
• 26.3. Market Revenue, by Type (2017-2030)
• 26.4. Market Revenue, by Drug Type (2017-2030)
• 26.5. Market Revenue, by Therapeutic Area (2017-2030)
• 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Process (2017-2030)
• 27.3. Market Revenue, by Type (2017-2030)
• 27.4. Market Revenue, by Drug Type (2017-2030)
• 27.5. Market Revenue, by Therapeutic Area (2017-2030)
• 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Process (2017-2030)
• 28.3. Market Revenue, by Type (2017-2030)
• 28.4. Market Revenue, by Drug Type (2017-2030)
• 28.5. Market Revenue, by Therapeutic Area (2017-2030)
• 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Charles River Laboratories International Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Eurofins Scientific Limited
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Frontage Laboratories Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Galapagos NV
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. General Electric
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Laboratory Corporation of America Holdings
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Thermo Fisher Scientific Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Syngene International Limited
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. WuXi AppTec
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports